/ /

  • linkedin
  • Increase Font
  • Sharebar

    Anti-factor D reduces GA progression 20%

    Dr. WilliamsBy Michelle Dalton, ELS; Reviewed by David F. Williams, MD, MBA

    Edina, MN—A phase II study of a humanized monoclonal antibody fragment that binds factor D has shown a 20% reduction in slowing geographic atrophy (GA) progression over 18 months, according to David F. Williams, MD, MBA.

    The MAHALO study of lampalizumab (formerly FCFD4514S, Genentech) also showed no unexpected or unmanageable serious adverse events, said Dr. Williams, who is a partner at VitreoRetinal Surgery, PA, Edina, MN, and an assistant clinical professor of ophthalmology, University of Minnesota, Minneapolis.

    “The clinical implications of the phase II results, if confirmed in a future phase III trial, are profound,” Dr. Williams said. “It would represent a seminal moment in ophthalmology—the first time that complement inhibition would show a positive therapeutic effect in an ophthalmic disease.

    “This would herald a new era of treatment for a major unmet need—slowing GA progression due to age-related macular degeneration (AMD) and preserving visual function for people with a previously untreatable disease,” he added.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results